Diabetes, family history and extension of coronary atherosclerosis are strong predictors of adverse events after PTCA: a one year follow-up study

L’uso di stent con sirolimus e’ significativamente associate alla riduzione della mortalita’ totale e della morbidita’ cardiovascolare sia a 6 mesi che a 12 mesi post-PTCA.

Stent nudi e stent medicati con sirolimus nel registro RESTEM

Livelli ridotti di cistatina C nell’infarto miocardico acuto vs. angina instabile, aneurisma aortico e controlli normali

Clinical predictors of adverse events in a 1 year follow-up study post-PCI

La simvastatina riduce le lipoproteine aterogene in pazienti con coronaropatia prematura: effetti delle statine “beyond-cholesterol”

Small, dense low-density lipoproteins are predictors of cardio- and cerebro-vascular events in subjects with the metabolic syndrome.

Use of stents with sirolimus is significantly associated with a reduction in mortality and cardiovascular morbidity at 6- and 12-months post-PTCA

Diabetes, family history and extension of coronary atherosclerosis are strong predictors of adverse events post-PTCA: a 1 year follow-up study

La simvastatina riduce le lipoproteine aterogene in pazienti con coronaropatia prematura: effetti delle statine “beyond-cholesterol”

Risultati del follow-up di 6 mesi in 100 pazienti con stent medicato con rapamicina rispetto ad altri 100 con stent tradizionale

Coronarografia diagnostica: evoluzione temporale in relazione ai progressi della PTCA

Accumulation of apoE-enriched triglyceride-rich lipoproteins in patients with coronary artery disease.

Triglycerides (TGs) are vehicled by multiple particles with different abilities to promote atherosclerosis. Among plasma TG-rich lipoproteins (TRLs), subspecies may or may not contain apolipoprotein E (apoE) molecules: in this study, we evaluated the relative contribution of apoE-rich and apoE-poor TRLs to coronary atherosclerosis. We selected a group of males with premature coronary artery disease (CAD) without any of the classical nonlipid risk factors and/or high plasma lipid levels and evaluated the plasma concentration of TRL subspecies in comparison with healthy controls. Patients with CAD and controls had total cholesterol and TG levels within the normal range (despite slightly, even…

Relazione tra il size delle LDL e l’estensione della malattia vasale coronarica in 72 pazienti maschi sottoposti a coronarografia diagnostica

Il diabete, la familiarita’ per malattie cardiovascolari e l’estensione della malattia vasale quali predittori degli eventi clinici ad 1 anno di follow-up post-PTCA

Uso degli stent medicati con rapamicina in pazienti con situazioni anatomiche o cliniche che favoriscono la restenosi: risultati del follow-up di 6 mesi su primi 100 pazienti

LDL peak particle size and the extension of coronary atherosclerosis in 72 patients that underwent an angiographic exam

Dati del follow-up di 6 mesi sui primi 100 pazienti con stent medicati con rapamicina, con situazioni anatomiche e cliniche favorenti la restenosi

Dati di mortalita’ e morbilita’ del follow-up condotto su 123 pazienti sottoposti ad angioplastica coronarica

Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial

Background The best treatment option for patients with type 2 diabetes in whom treatment with metformin alone fails to achieve adequate glycaemic control is debated. We aimed to compare the long-term effects of pioglitazone versus sulfonylureas, given in addition to metformin, on cardiovascular events in patients with type 2 diabetes. Methods TOSCA.IT was a multicentre, randomised, pragmatic clinical trial, in which patients aged 50–75 years with type 2 diabetes inadequately controlled with metformin monotherapy (2–3 g per day) were recruited from 57 diabetes clinics in Italy. Patients were randomly assigned (1:1), by permuted blocks randomisation (block size 10), stratified by site and…

Clinical predictors of adverse events in a 1 year follow-up study post-PTCA.

Correlazione in 309 pazienti coronaropatici tra i livelli di HDL-colesterolo e l’estensione della coronaropatia

Effects “beyond-cholesterol” of statins: simvastatin reduces the levels of atherogenic lipoproteins in patients with premature coronary artery disease

Simvastatin reduces the levels of ApoE-containing triglyceride-rich lipoproteins in men with premature coronary artery disease

Accumulation of remnant-like particles in normolipidemic men with premature coronary artery disease

USE OF THE DRUG ELUTING STENTS WITH RAPAMICIN IN PATIENTS WITH ANATOMICAL OR CLINICAL PATTERNS FAVOURING RESTENOSIS: RESULTS OF A 6-MONTHS FOLLOW-UP ON THE FIRST 100 PATIENS.

Drug eluting stents's use in patients with anatomical or clinical patterns favouring restenosis: a 6-months follow-up study

Effetti “beyond-cholesterol” delle statine: la terapia con simvastatina riduce le lipoproteine aterogene in pazienti con coronaropatia prematura